There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
Future Market Insights2d
Super Generics Industry to Double by 2033, Reaching USD 413 Billion with a 7.2% CAGR
Market Growth: The super generics market is forecasted to grow from USD 205 billion in 2023 to USD 413 billion by 2033, at a ...
New York Post11d
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s permission. “Generic drugs provide additional treatment options which ...
pharmaphorum5d
A history of: The generics industry
The big Indian generic manufacturers are receiving competition from new upstarts, and from innovative pharma companies producing generics of their own drugs. Drugs that a few years ago could get ...
Medscape11d
FDA Approves Second Generic Daily GLP-1 Drug for T2D
The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...
pharmaphorum8d
Innovation and development of generic pharmaceuticals
Once the patent of a brand-name drug expires, generic drugs are able to enter the market. Essentially, generics are virtually identical to the brand-name version, being just as effective and ...
US FDA approves Hikma's generic version of Novo's diabetes drug Victoza
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...